PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

  title={PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.},
  author={Melissa A Deri and Brian M. Zeglis and Lynn C. Francesconi and Jason S. Lewis},
  journal={Nuclear medicine and biology},
  volume={40 1},

Figures and Tables from this paper

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients

The production of 89Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of  89Zr-based immuno-PET in oncology will be discussed, and the ongoing development of new 89ZR-labeled antibodies directed against novel tumor targets is expected to expand applications in the medical imaging.

Insight into the Development of PET Radiopharmaceuticals for Oncology

This review outlines the fundamentals of radiotracer design, with respect to the selection of an appropriate pharmacophore and provides a guideline for the proper selection of a radionuclide and the appropriate labeling strategy to access a tracer with optimal imaging qualities.

Immuno-PET: Design options and clinical proof-of-concept

This paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs of radiopharmaceutical drug development in immuno-PET approaches.

89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges

This review outlines the recent developments in the field of 89Zr-labeled bioactive molecules, their potential and application in PET imaging and beyond, as well as remaining challenges.

Radiopharmaceuticals developed for 89Zr-Immuno-PET

This review provides a general overview of the potential of molecules labeled with 89Zr radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies.

Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging.

This review aims to provide the nuclear imaging field with a resource covering the path of the entire radioimmunoconjugate as it travels through the body and the fate of the radionuclide itself, as its course can diverge from the antibody under certain circumstances.

Tumour targeting with radiometals for diagnosis and therapy.

An introduction to the imaging and therapy modalities exploited in nuclear medicine and a discussion of the multi-component strategy used in radiopharmaceutical development, known as the bifunctional chelate (BFC) method are opened.

Chemoenzymatic Strategy for the Synthesis of Site-Specifically Labeled Immunoconjugates for Multimodal PET and Optical Imaging

A chemoenzymatic strategy for the construction of multimodal PET/OI immunoconjugates that have been site-specifically labeled on the heavy chain glycans is developed, reliably producing well-defined and immunoreactive conjugates labeled with 89Zr, Alexa Fluor 680, or an easily and precisely tuned mixture of the two reporters.

The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies.

In this protocol, the prostate-specific membrane antigen targeting antibody J591 will be used as a model system to illustrate the bioconjugation of the bifunctional chelator DFO-isothiocyanate to an antibody, the radiosynthesis and purification of a 89Zr-DFO-mAb radioimmunoconjugate, and in vivo PET imaging in a murine model of cancer.

In vivo Imaging Technologies to Monitor the Immune System

The modalities and immunologic targets that have thus far been explored are described, with the goal of promoting and guiding the future development and application of novel imaging technologies.



The next generation of positron emission tomography radiopharmaceuticals in oncology.

The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals.

A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

A practical guide to the construction of radiometal-based PET bioconjugates, in which the design choices and synthetic details of a wide range of biomolecular tracers from the literature are collected in a single reference.

Cerenkov Luminescence Imaging of Medical Isotopes

These studies represent the first, to the authors' knowledge, quantitative assessment of CLI for measuring radiotracer uptake in vivo and show excellent promise as a potential new imaging modality for the rapid, high-throughput screening of radiopharmaceuticals.

Antibodies for Molecular Imaging of Cancer

Antibody imaging can provide a sensitive, noninvasive means for molecular characterization of cell surface phenotype in vivo, which can in turn guide diagnosis, prognosis, therapy selection, and monitoring of treatment in cancer.

Unconventional Nuclides for Radiopharmaceuticals

The physical characteristics of 60 radionuclides, including β+, β−−, γ-ray, and α-particle emitters, which have the potential for use in the design and synthesis of the next generation of diagnostic and/or radiotherapeutic drugs are described.

Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

SPECT and PET technology has been around for decades, but its use remained limited because of the limited availability of relevant isotopes which had to be produced in nuclear reactors or particle accelerators, but the introduction of the small biomedical cyclotron, the self-contained radionuclide generator and the dedicated small animal or clinical SPECT andPET scanners to hospitals and research facilities has increased the demand for SPect and PET isotopes.

Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach.

It is concluded that in vivo application of the Staudinger ligation in a pretargeting approach in mice is not feasible, since this ligation reaction is not bioorthogonal and efficient enough.

Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions

The full characterization of CLI is reported using the positron-emitting radiotracer 89Zr-DFO-trastuzumab for target-specific, quantitative imaging of HER2/neu-positive tumors in vivo, providing the first demonstration of the feasibility of using CLI for true image-guided, intraoperative surgical resection of tumors.

The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.

This review focuses on the biological probes and processes that have been examined, in additiom to the preclinical and clinical findings with nonstandard radiometals: copper-64, zirconium-89, and yttrium-86.

PET tracers based on Zirconium-89.

With well-developed radiochemistry, commercial availability of chelating agents for (89)Zr labeling, increasingly widely available isotope supply, as well as successful proof-of-principle in pilot human studies, it is expected that PET imaging with (89]Zr-based tracers will be a constantly evolving and highly vibrant field in the near future.